Further characterization of the five CD133 promoters, including protein-protein interactions and epigenetic regulations, must allow us to identify bona fide targets that define tumor stemness, and facilitate the development of TSLC-targeted therapies to eradicate human malignancies. This evidence concerns the gene PROM1 and neoplasm.